Contact l Sitemap

home industries issues reasearch weblog press

Home  » Industries » Pharmaceuticals

Pharmaceuticals

The cost of prescription drugs has never been higher, and pharmaceutical companies have never spent more persuading consumers that they need drugs they've never heard of for illnesses they didn't know they had. Drug companies are also spending millions defending patents and persuading the FDA to approve new drugs ever faster. Meanwhile, developing countries go without desperately needed drugs because pharmaceutical companies fear that lowering prices for the neediest is a slippery slope. Big Pharma says high prices fund research and innovation.


Sun Pharma, India's Biggest Drug Producer, Violated Manufacturing Rules
by Richard SmallteacherCorpWatch Blog
December 25th, 2015
Sun Pharma, India's biggest drug manufacturer, has been sent a warning letter about violations of manufacturing regulations at its Halol plant in Gujarat by the United States Food and Drug Administration (FDA). Indian companies supply as much as 40 percent of the drugs sold in the U.S.

U.S. Doctors Associations Cancel Collaborations With Coca-Cola After Protests
by Pratap ChatterjeeCorpWatch Blog
October 1st, 2015
Three major U.S. medical associations - the American Academy of Family Physicians, the American Academy of Pediatrics and the American College of Cardiology - have bowed to pressure from activist doctors to stop accepting corporate donations from Coca-Cola. The campaigners say Coke exerted undue influence over the medical groups.

Eli Lilly Raised U.S. Prices Of Diabetes Drug 700 Percent Over 20 Years
by Pratap ChatterjeeCorpWatch Blog
November 2nd, 2016
Eli Lilly, an Indianapolis based company, that has sold insulin products to diabetes patients since 1921, has quietly raised some U.S. prices 700 percent in the last 20 years by marketing so-called improved versions to consumers. Novo Nordisk, a Danish company, has also profited handsomely from this practice.

Six Novartis Executives Charged In Illegal Drug Rebate Scheme In South Korea
by Richard SmallteacherSpecial to CorpWatch
August 11th, 2016
Six executives of Swiss pharmaceutical giant Novartis have been indicted in a South Korean bribery scandal. The indictments follow similar charges in China, Turkey and the U.S. and allegations of falsifying drug trial data in Japan. Korean prosecutors have recommended that Novartis sales be suspended for six months.

Gilead Avoided $10 Billion In Taxes On Over Priced Hepatitis C Drugs
by Richard SmallteacherSpecial to CorpWatch
July 13th, 2016
Gilead Sciences Inc., a California based pharmaceutical company, has avoided paying $10 billion in taxes by moving its patents to Ireland. This is despite the fact that one of its most profitable drugs was developed with U.S. taxpayer money, according to a new report from Americans for Tax Fairness.

Ovarian Cancer Victims Win Talcum Powder Lawsuits Against Johnson & Johnson
by Richard SmallteacherCorpWatch Blog
April 4th, 2016
Johnson & Johnson has been sued by over 1,200 women who blame the company's talcum powder products for their ovarian cancer. Not only are U.S. courts beginning to agree with them, juries have started to award victims millions of dollars in compensation.

Drugs Tested By GVK Biosciences Banned From European Union
by Pratap ChatterjeeCorpWatch Blog
July 27th, 2015
Hundreds of drugs tested in India have been banned from sale in the European Union after French inspectors found flaws in clinical trials conducted by GVK Biosciences, a company based in Hyderabad. The Indian government has threatened to take legal action against the ban under international trade rules.

DaVita Pays $895 Million To Settle Kidney Treatment Fraud Claims
by Richard SmallteacherCorpWatch Blog
May 14th, 2015
DaVita, a company that provides health care to patients with kidney problems, has agreed to pay $495 million to settle whistleblower complaints that the company conspired to overcharge the U.S. government. This is in addition to the $400 million that the company had to pay out last year.

Actavis Sued To Stop Forced Switch To New Alzheimer's Drug
by Richard SmallteacherCorpWatch Blog
September 16th, 2014
Actavis, the world's third-largest generic drug manufacturer, has been sued by New York state to prevent it from forcing patients to take a new version of a popular Alzheimer's drug. The company is attempting to hook patients on an extended release version before its U.S. patent expires next year.

Gilead Sciences Under Investigation for Over Charging for Hepatitis C Pill
by Pratap ChatterjeeCorpWatch Blog
July 21st, 2014
Gilead Sciences of San Francisco is under investigation by the U.S. Senate Finance Committee for charging $84,000 for a 12 week course of a new drug to treat hepatitis C. Gilead sells the exact same course for $900 in poor countries like Egypt and India.

Displaying 1-10 of 34  
Next >> 
Last Page » 
« Show Complete List »